A citation-based method for searching scientific literature

AnnCatherine M Downing, Bruce J Kinon, Brian A Millen, Lu Zhang, Lin Liu, Margarita A Morozova, Ronald Brenner, Tami Jo Rayle, Laura Nisenbaum, Fangyi Zhao, Juan Carlos Gomez. BMC Psychiatry 2014
Times Cited: 66







List of co-cited articles
1061 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
56

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
176
37

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
76
36




Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison.
David H Adams, Lu Zhang, Brian A Millen, Bruce J Kinon, Juan-Carlos Gomez. Schizophr Res Treatment 2014
46
34

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
22






AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Robert E Litman, Mark A Smith, James J Doherty, Alan Cross, Shane Raines, Lev Gertsik, Stephen R Zukin. Schizophr Res 2016
46
26

Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
563
15


Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
138
15

Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.
W Liu, A C M Downing, L M Munsie, P Chen, M R Reed, C L Ruble, K T Landschulz, B J Kinon, L K Nisenbaum. Pharmacogenomics J 2012
36
25

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
13

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.
Mitsumasa Kurita, Terrell Holloway, Aintzane García-Bea, Alexey Kozlenkov, Allyson K Friedman, José L Moreno, Mitra Heshmati, Sam A Golden, Pamela J Kennedy, Nagahide Takahashi,[...]. Nat Neurosci 2012
177
13

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
129
13

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Stefan Leucht, Andrea Cipriani, Loukia Spineli, Dimitris Mavridis, Deniz Orey, Franziska Richter, Myrto Samara, Corrado Barbui, Rolf R Engel, John R Geddes,[...]. Lancet 2013
13


An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Suresh Durgam, Anju Starace, Dayong Li, Raffaele Migliore, Adam Ruth, György Németh, István Laszlovszky. Schizophr Res 2014
110
13

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
13

Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs.
Miguel Fribourg, José L Moreno, Terrell Holloway, Davide Provasi, Lia Baki, Rahul Mahajan, Gyu Park, Scott K Adney, Candice Hatcher, José M Eltit,[...]. Cell 2011
194
12


Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
297
12

Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.
Shen Yin, Meredith J Noetzel, Kari A Johnson, Rocio Zamorano, Nidhi Jalan-Sakrikar, Karen J Gregory, P Jeffrey Conn, Colleen M Niswender. J Neurosci 2014
82
12

Metabotropic glutamate receptors: from the workbench to the bedside.
F Nicoletti, J Bockaert, G L Collingridge, P J Conn, F Ferraguti, D D Schoepp, J T Wroblewski, J P Pin. Neuropharmacology 2011
417
12

Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782.
Hilde Lavreysen, Xavier Langlois, Abdel Ahnaou, Wilhelmus Drinkenburg, Paula te Riele, Ilse Biesmans, Ilse Van der Linden, Luc Peeters, Anton Megens, Cindy Wintmolders,[...]. J Pharmacol Exp Ther 2013
51
13


Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
10

Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor.
Tetsuaki Hiyoshi, Toshiyuki Marumo, Hirohiko Hikichi, Yasumitsu Tomishima, Hiroki Urabe, Tomoko Tamita, Izumi Iida, Akito Yasuhara, Jun-ichi Karasawa, Shigeyuki Chaki. J Pharmacol Exp Ther 2014
23
30

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
127
10

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
259
10


The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
293
10

Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.
P Jeffrey Conn, Arthur Christopoulos, Craig W Lindsley. Nat Rev Drug Discov 2009
771
10

ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.
Jeffrey A Lieberman, Robert E Davis, Christoph U Correll, Donald C Goff, John M Kane, Carol A Tamminga, Sharon Mates, Kimberly E Vanover. Biol Psychiatry 2016
40
17

Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
John M Kane, Stephen Zukin, Yao Wang, Kaifeng Lu, Adam Ruth, Krisztián Nagy, István Laszlovszky, Suresh Durgam. J Clin Psychopharmacol 2015
101
10

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
134
10

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Jeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, Marvin S Swartz, Robert A Rosenheck, Diana O Perkins, Richard S E Keefe, Sonia M Davis, Clarence E Davis, Barry D Lebowitz,[...]. N Engl J Med 2005
10

Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
Scott A Schobel, Nashid H Chaudhury, Usman A Khan, Beatriz Paniagua, Martin A Styner, Iris Asllani, Benjamin P Inbar, Cheryl M Corcoran, Jeffrey A Lieberman, Holly Moore,[...]. Neuron 2013
317
10


Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Anantha Shekhar, William Z Potter, Jeffrey Lightfoot, John Lienemann, Sanjay Dubé, Craig Mallinckrodt, Frank P Bymaster, David L McKinzie, Christian C Felder. Am J Psychiatry 2008
316
10

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
Dragana Bugarski-Kirola, Thomas Blaettler, Celso Arango, Wolfgang W Fleischhacker, George Garibaldi, Alice Wang, Mark Dixon, Rodrigo A Bressan, Henry Nasrallah, Stephen Lawrie,[...]. Biol Psychiatry 2017
47
14


Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats.
Agnieszka Nikiforuk, Piotr Popik, Karla U Drescher, Marcel van Gaalen, Ana-Lucia Relo, Mario Mezler, Gerard Marek, Hans Schoemaker, Gerhard Gross, Anton Bespalov. J Pharmacol Exp Ther 2010
59
10

CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro, James A Monn, Darryle D Schoepp, Gerard J Marek. Neuropharmacology 2013
67
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.